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This paper presents the strengths, weaknesses, opportunities, and threats for Artificial Intelligence 
(AI) as applied to long-term respiratory disease management. This analysis will help to identify, 
understand, and evaluate key aspects of the technology as well as the various internal/external 
forces which influence its success in this application space. Such understanding is instrumental to 
ensure judicial planning and implementation with suitable safeguards being considered. AI has the 
potential to radically change how respiratory disease management is conducted and may help 
clinicians to realise new treatment paradigms. The application of AI is clearly not specific to 
respiratory disease management; however it is a chronic disease that requires on-going 
monitoring and well evidenced decision making regarding treatment pathways or medication 
modification. This work emphasises the current position of AI as applied to respiratory disease 
management and identifies the issues to help develop strategic directions to ensure successful 
implementation, evidenced by ubiquitous acceptance and uptake. 
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1. INTRODUCTION 
As medical technology gets smaller, smarter, and 
more able to process large volumes of data, there 
are opportunities to take devices which are 
hospital-based and realise them as a small portable 
devices, facilitating mobile and remote healthcare 
strategies. Additionally there is a growing trend to 
embed intelligence into such devices enabling them 
to make decisions based on ongoing preferences 
and inputs, such as biomedical measurements. To 
this end a software platform, not a clinician, may 
inform or produce medical decisions about 
treatment and interventions. Furthermore, 
emergence of pervasive communications and 
Internet of Things (IoT) technologies ensure 
significant data can be relayed to clinical experts 
and cloud-based software platforms enabling 
decision support. 
There has been a wide range of recent studies 
where AI has been applied to assist with clinical 
decisions such as the automated diagnosis of skin 
cancer [1], bone abnormalities [2], assistance with 
DNA sequencing [3], and supporting surgery 
scheduling [4]. Diagnosis of obstructive lung 
disease is an area of potential promise [5]; it could 
increase detection accuracy [6] and automate 
screening to increase patient throughput.  
The subject of this recent research has focused 
around machine learning-based approaches to 
classification and recognition of activities, notably 
within the area of Big Data. Generally, these 
machine learning approaches are within 2 broad 
categories - supervised and unsupervised.  
Supervised machine learning builds a classification 
model through providing it with annotated data, 
such as images tagged with enumeration 
representation conditions, such as healthy skin, 
unhealthy skin, or indeterminate. This model is then 
applied to previously unseen data to provide a 
classification.  
Unsupervised machine learning leverages 
unlabelled data to correlate data within a dataset. 
This enables analysis of data such as matching 
similar data in groups/clusters or identification of 
anomalies/outliers. Yu et al. [1] leveraged 
supervised machine learning to produce a model 
which accurately classified the potential for 
dermoscopy images to be cancerous, Deep 
Convolutional Neural Networks (CNN) were used to 
realise this solution producing a viable trained 
model from 900 images. Jagadev et al. [2] 
implemented supervised machine learning to 
produce a Support Vector Machine-based classifier 
capable of identifying images of blood smear tests 
which are likely to have a form of leukaemia.  
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Celesti et al. [3] surveyed studies which involved 
AI-based analysis of genomics data to identify 
conditions and anomalies. These surveyed studies 
used supervised and unsupervised machine 
learning as dictated by their use case. Typically, 
supervised learning was employed to identify 
conditions using a model built from training data 
whereas unsupervised machine learning was used 
to identify anomalies.  
In recent years AI research has had a focus on 
using machine learning, however, works exist 
which have devised Decision Support Systems 
(DSS) support systems and traditional, tailored, 
classification algorithms. Xiang et al. [4] have 
produced a DSS incorporating custom classification 
algorithms to optimise scheduling of surgical 
procedures giving operational restraints and 
required resources, such as availability of an 
operation theatre and supporting staff.   This has 
proven to optimise efficiency and increase health 
outcomes. 
All illness management may benefit from AI; 
respiratory disease management is an enduring 
key medical theme which encompasses Asthma, 
chronic obstructive pulmonary disease (COPD), 
pulmonary hypertension, bronchiectasis, sleep 
apnoea, etc. [7] and attributes to around 20% of UK 
deaths [8]. COPD is ranked as the third most 
common global cause of death in the last decade 
[9].  
Respiratory disease is commonly diagnosed and 
monitored using Spirometry (lung function test) 
which evaluates the volume of air expelled from the 
lungs (forced vital capacity) as well as the rate at 
which the air is expelled (forced expiratory volume) 
[10]. A similar, simpler, meter measuring the peak 
expiratory flow (PEF) is often used in everyday 
clinical practice (often referred to as peak flow 
meter). This technology has been mechanical in 
nature but in recent years has been realised as 
electronic measurement devices with wireless 
connectivity, typically Bluetooth. Other diagnosis 
techniques which complement spirometry include 
the use of biomarkers for COPD or lung cancer [11, 
12]. Such biomarkers may be realised as 
implantable monitors or home test kits; employing 
AI would make a powerful point-of-care system. 
There are clear correlations between air pollution 
and respiratory disease, mortalities, and outpatient 
admissions [13]. Approximately 3 million people die 
each year from COPD, which is estimated to be 
around 6% of all deaths worldwide. It is also 
determined that some 235 million people suffer 
from asthma [7]. While significant progress has 
been made to predict, monitor and treat respiratory 
disease [14-16] there is still significant exploration 
required.  
Given the types of data and availability of datasets 
a swathe of AI techniques can be used within this 
domain. Supervised machine learning may be used 
to build a classification model which may be used 
to indicate when COPD symptoms are likely to 
deteriorate. This model may be produced from an 
annotated dataset leveraging environmental 
metrics, biomarkers, an individual’s medical history 
and current state. Unsupervised machine learning 
may be applied to a large dataset gathered from 
sufferers to help identify factors which can 
contribute to, or prevent, COPD flare ups.   
A DSS may be produced from domain knowledge 
to inform, prompt, and advise respiratory disease 
suffers in a tailored fashion. This DSS may take 
inputs from PEF measurements, environmental 
data, and supervised machine learning 
classification of an individual’s parameters. The 
realisation of such a solution will be the subject of 
future work and will be informed by the quality and 
quantity of data that can be reliably obtained from 
sufferers of respiratory diseases. 
2. S.W.O.T. ANALYSIS 
An analysis of the strengths, weaknesses, 
opportunities, and threats of AI’s application to 
respiratory disease management is an essential 
aspect of understanding the potential of the 
technology as well as the paths to application. The 
strengths and weaknesses are with respect to the 
internal aspects of AI. Any identified weaknesses 
may be addressed via technological revisions. The 
opportunities and threats are with respect to the 
external aspects; these include other technologies, 
public perception of the technology, financial 
climate, etc. Threats are addressed via methods 
such as legislation and public education strategies, 
although are more difficult to change. The use of 
SWOT analysis gives a panoramic and 
comprehensive perspective of the state of the 
technology in the specific sector. It is a universal 
method which creates a usable examination which 
may act as a starting point to tackle the challenges. 
2.1 Strengths 
AI boasts the ability to recognise objects in images, 
transcribe speech, control machines, analyse DNA 
to detect genomic conditions, etc. [17]. Such 
technological strengths expedite the delivery of 
bespoke personalised care for respiratory disease 
management. AI’s ability to learn, find patterns, 
make decisions, etc. This may be facilitated 
through sensor measurements from spirometers, 
inhaler and medication usage, biomarkers, etc. In 
addition, qualitative data may be incorporated from 
active assistants/chat bots to understand feelings, 
pain, anxiety, breathlessness, etc. Such solutions 
will assist with making informed machine decisions 
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leading to medication alteration, clinician 
intervention or hospitalisation. AI could predict a 
respiratory disease decline, such as an asthma 
attack, before the patient even considers there to 
be anything untoward or peak flow measurements 
show a notable decline in lung function.  The 
abundant recorded data that can be stored from the 
vast array of patients can help the training of 
accurate AI models, particularly through deep 
learning approaches. It is recognised that early 
detection of exacerbations in COPD can increase 
positive outcomes and reduce hospital admissions; 
telehealth-based systems interventions can 
decrease the costs associated with COPD patients 
[18] and promote better self-management [19, 20]. 
2.2 Weaknesses 
In late 2017 mainstream technical news sources 
published reports with taglines such as “No one 
really knows how the most advanced algorithms do 
what they do” [21]. This suggests that the decisions 
that AI makes can be unexplainable or beyond 
logic. For example, chip maker Nvidia tested a car 
controlled by AI and later reported that the vehicle 
didn’t follow a single instruction provided by the 
programmers, instead using an algorithm that it had 
taught itself. While this may be good for attention-
grabbing headlines it creates disquiet for those who 
are looking to AI to intelligently manage the health 
decisions of the chronically ill. The vehicle in the 
test conducted itself appropriately and completed 
the task very well but the engineers couldn’t 
describe how it did it [21]. This is not an isolated 
report but a growing trend [22]. Furthermore, some 
complex AI systems have been described as 
“inscrutable” as it is not possible to make the AI 
system explain why it made certain decisions; such 
inability for humans to understand the decision-
making processes of the system creates significant 
risk. These inscrutable solutions typically leverage 
machine learning based approaches to AI. When 
that risk is applied to chronic diseases like COPD 
such inscrutable systems are unacceptable and it 
would not be possible to verify if a death was an 
unavoidable outcome or a bizarre AI decision. 
Validation of medical technology requires 
substantial clinical testing which costs time and 
money; however system reliability and observability 
are two of the key parameters of any system under 
test. AI in healthcare cannot be a leap of faith into 
the unknown and capricious systems may have no 
future in this space. To this end, such solutions 
may be limited to offer insight to inform decisions to 
be made by medical practitioners. 
2.3 Opportunities 
With respiratory disease being a significant strain 
on healthcare resources it is advantageous to push 
the monitoring of patients into the community to 
keep patients out of hospital [18]. Smart homes are 
increasing popular [23] and there may be 
opportunities to integrate medical devices with 
these networks. Implementing smart healthcare 
devices into the community also helps to drive 
technology and services into remote areas to 
address the recognised issues of rural communities 
being last to get the latest technical services [24]. 
Having intelligent sensors and systems that are 
continually monitoring your wellness is likely to 
have measurable health benefits over occasional 
clinic visits; such monitoring resolution will assist 
with faster responses to deteriorations as well as 
better diagnoses. This principle has been proven 
already with smart implanted insulin pumps which 
actively monitor blood glucose levels and 
automatically medicate to exacting levels 
accordingly [25]. Further emerging technologies 
such as stretchable electronics [26] and long range 
low power communication systems [27] increase 
the potential for effective technology deployment. 
2.4 Threats 
The literature shows limited work on AI and 
telemetry for respiratory disease monitoring [28] 
which means it is not as well understood as some 
other areas of study. However, some key 
explorations on the use of machine learning for 
respiratory disease diagnosis in clinical settings 
serve to effectively highlight the value of developing 
the technology [29-31]. Other external threats may 
impede the uptake of AI for respiratory disease 
management including the fear of lawsuits against 
the system creator if AI is proven to have made a 
poor judgement or an obvious mistake. Likewise, 
the over-expectation of investors, technical 
communities and medical professionals, fears over 
security of data and hacking, poor investment into 
the technology, user error of any aspect of the 
system, issues with poor battery performance for 
portable devices, and global economics which 
demands continual cost cutting will all serve to 
threaten successful adoption of the technology. 
High profile figures such as the late Professor 
Stephen Hawking have done little to help the public 
perception of AI [32]. Furthermore the notoriously 
slow uptake of new technology in healthcare [33] 
may result in the technology being quickly 
outdated, especially in the context of AI technology 
changing so rapidly.  
A notable high profile AI failure will no doubt cast a 
long shadow over the trust of AI implementation for 
some time; in March 2018 an autonomous car 
being driven by AI was involved in a fatal 
pedestrian accident [34]. Internet commentators 
reasoned that the outcome would have been the 
same regardless of whether a computer or a 
person was under control of the vehicle, 
nonetheless  the headline will still capture the 
imagination of those already fearful of machines 
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making life and death decisions. These issues are 
real and cannot be overcome easily; objections will 
remain and as such the technology could struggle 
to enjoy widespread acceptance without significant 
research and validation of medical AI systems. 
While automotive AI applications are clearly distinct 
from healthcare applications the public perception 
may not be adequately informed to appreciate the 
different techniques and technologies utilised.  
3. CONCLUSIONS 
The potential for impact and reduced costs for 
respiratory disease management is clear, however 
there are also significant obstacles to 
implementation and the approval processes in 
healthcare could make the new technology lag 
behind AI implementation in other sectors; 
healthcare could therefore be the last sector to 
experience the benefits of the IoT/AI revolution. 
Correct implementation however will fundamentally 
enable fast reactions to emergencies in the short 
term and disease progression management in the 
long term. It will also have the capacity to address 
the increased management complications 
presented by multiple chronic conditions (MCC). 
 Non-medical devices purporting to contain AI may 
serve to impede authorised application in clinical 
practice as if these consumer electronics lifestyle 
devices are of questionable trustworthiness they 
may complicate acceptance of AI in automated 
healthcare decision making. General 
recommendations for well-managed 
implementation includes ensuring the technology is 
not hurried to meet industry expectations, the use 
of valid training datasets taken from a cross section 
of communities and diseases, ongoing healthcare 
cost evaluations, and the acknowledgement that AI 
is still in its infancy and has significant maturing to 
do before being ready for such an audacious task.  
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